Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

Overview of attention for article published in BMC Gastroenterology, March 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 27 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 2,315 followers.

RT @DrJHK: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellul…

04 Apr 2022

Reply Repost Favourite

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis https://t.co/mhKZ7hbrMU

03 Apr 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.